Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Guilan Sun"'
Autor:
Shikai Wang, Min Feng, Yu Fang, Liang Lv, Guilan Sun, Shanfei Cheng, Weiquan Huang, Shengliang Yang, Ping Guo, Mincai Qian, Huanxin Chen
Publikováno v:
BMC Psychiatry, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Aim To analyze the changes of chronotypes in patients with depression before and after treatment, and explore the effects of different chronotypes on antidepressant treatment and the dimensions of common symptoms in patients with depression.
Externí odkaz:
https://doaj.org/article/b4916a8a07cd45f1b2e8ef9346aebd72
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 3, Pp 447-458 (2023)
Abstract CSPCHA115 is a highly selective and potent antagonist of chemoattractant receptor‐homologous molecule expressed on TH2 cells (CRTH2). This study aimed to evaluate the pharmacokinetics (PKs), safety, and tolerability of single and multiple
Externí odkaz:
https://doaj.org/article/90872df5c74347189a716462eba7bf24
Autor:
Pin Zhang, Binghe Xu, Lin Gui, Wenna Wang, Meng Xiu, Xiao Zhang, Guilan Sun, Xiaoyu Zhu, Jianjun Zou
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-9 (2021)
Abstract Background Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models. This first-in-human study was conducted to evaluate the tolerability, pharmacokinetic
Externí odkaz:
https://doaj.org/article/d90b26c5c0984e26bded0075c4324f98
Publikováno v:
Journal of Global Oncology, Vol 3, Iss 6, Pp 692-700 (2017)
Purpose: We aimed to quantify Chinese cancer survivors’ perceived needs for survivorship care and to evaluate whether these needs could impact their willingness to use traditional Chinese medicine (TCM). Methods: We conducted a cross-sectional surv
Externí odkaz:
https://doaj.org/article/08e395b16c394298a2aca5d844bdc010
Autor:
Jingjing Yang, Lili Lin, Qihe Long, Qian Zhang, Guilan Sun, Liang Zhou, Qingyu Wang, Jun Zhu, Fanfan Li, Wei Hu
Publikováno v:
BioDrugs. 36:393-409
Pertuzumab is a humanized monoclonal antibody for the treatment of breast cancer. HLX11 is a biosimilar of pertuzumab developed by Shanghai Henlius Biotech, Inc. We conducted a bioequivalence study for HLX11 and pertuzumab (United States [US]-, Europ
Autor:
Xiaoyan Guo, Zhenggui Zhang, Guilan Sun, Shiwu Xiong, Yingchun Han, Guoping Wang, Cundong Li, Yabing Li, Yongjiang Zhang, Zhanbiao Wang
Publikováno v:
Crop Science.
Publikováno v:
Clinical and translational scienceREFERENCES.
CSPCHA115 is a highly selective and potent antagonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). This study aimed to evaluate the pharmacokinetics (PKs), safety, and tolerability of single and multiple ascending d
Autor:
Yu Fang, Ping Guo, Liang Lv, Min Feng, Hong Wang, Guilan Sun, Shikai Wang, Mincai Qian, Huanxin Chen
Publikováno v:
Asian Journal of Psychiatry. 82:103484
Autor:
Guilan Sun, Zihao Dong, Guangjing Li, Hezhen Yuan, Jiahao Liu, Xue Yao, Jiangjiang Gu, Honghong Wu, Zhaohu Li
Publikováno v:
Advanced Biology. :2200317
Autor:
Guilan Sun, Zhenggui Zhang, Shiwu Xiong, Xiaoyan Guo, Yingchun Han, Guoping Wang, Lu Feng, Yaping Lei, Xiaofei Li, Beifang Yang, Fangfang Xing, Minghua Xin, Huanxuan Chen, Yabing Li, Zhanbiao Wang
Publikováno v:
Agriculture, Ecosystems & Environment. 332:107946